SCHEMBL20190372

SCHEMBL20190372

FC(F)(F)c1ccc(-c2ccn3nccc3n2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 4/20 0.68
DYRK1A Q13627 1/20 0.55
TGFBR1 P36897 3/20 0.48
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KIF11 P52732 2/20 0.42
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
GFER P55789 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RCE1 Q9Y256 1/20 0.41
TOP1 P11387 2/20 0.40
AHR P35869 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348540 0.84 KDM4E (0.64) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL3498318 0.82 DYRK1A (0.63) SCN5ADYRK1ATGFBR1KDM4ENPC1
SCHEMBL20190623 0.81 SCN5A (1.00) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL3162678 0.80 DYRK1A (0.65) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL20191023 0.80 SCN5A (0.58) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL30118011 0.79 SCN5A (0.71) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL1348265 0.79 SCN5A (0.60) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL23572416 0.75 SCN5A (0.56) SCN5ADYRK1ATGFBR1PIK3CD
SCHEMBL16304131 0.75 SCN5A (0.59) SCN5ADYRK1ATGFBR1KDM4EALDH1A1
SCHEMBL23572409 0.74 SCN5A (0.55) SCN5ADYRK1ATGFBR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885DYRK1A 4493/4885TGFBR1 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.